Cyclin-dependent kinase 5 acts as a promising biomarker in clear cell Renal Cell Carcinoma

Liangsong Zhu1†, Rong Ding2†, Jianping Zhang1, Jin Zhang3* and Zongming Lin1*

Abstract

Background: This research provides the first evidence of CDK5 in ccRCC prognosis and correlation with different p21 expression in overall survival (OS) analysis.

Methods: The data from both of The Cancer Genome Atlas (TCGA) and Gene Expression of Normal and Tumor Tissue (GENT) were analyzed for determining the expression of CDK5 in kidney cancer. Tissue microarray that made by using 150 ccRCC samples was used in immunohistochemistry (IHC) analysis. A validation of OS cohort was extracted from Oncomine database.

Results: The CDK5 expression was significantly lower in cancer tissue compared with normal in TCGA \((p < 0.0001)\), GENT database also showed a relative low expression in kidney cancer. Among 150 ccRCC patients, low CDK5 was detected in 83 cases (55.3%), low p21 in 97 cases (64.7%). CDK5 was associated with the advanced TNM stage \((p = 0.042)\), and Fuhrman grade \((p = 0.035)\). Patients with lower CDK5 might be more likely to be aggressive status. According to the combination analysis of CDK5 and p21, patients in CDK5 low/p21 low group showed poorer survival rate, and no significant survival difference was observed in other groups. In the Cox multivariate analysis, the co-expression of CDK5 low/p21 low was identified as an independent prognostic factor in ccRCC patients.

Conclusions: Together, our findings provided the first evidence that CDK5 was acting as a promising biomarker in ccRCC patients, and co-expression of CDK5 and p21 is an independent prognostic for overall survival. IHC analysis of CDK5 and p21 on cancer tissues after surgery may help to evaluate and predict the outcome of ccRCC patients.

Keywords: CDK5, p21, ccRCC, Prognostic

Background

The incidence of renal cell carcinoma (RCC) has been increased in the past decades, RCC is also reported to be the 14th most common malignancy and most lethal urologic cancer [1, 2]. Nowadays, some researches reported that several environmental risk factors have been identified for the development of RCC, including hypertension, smoking, obesity, and diabetes [3, 4]. The clear cell renal cell carcinoma (ccRCC) is the most common pathological subtype which nearly account for 70–75%, the papillary RCC account for 10–16%, and chromophone RCC account for 5%. Since the Von Hippel-Lindau (VHL) disease tumor suppressor gene VHL is commonly inactivated in ccRCC, the tyrosine kinase inhibitors (TKIs) that modulate the \(pVHL-HIF-VEGF\) signaling pathway have showed treating benefit in patients with advanced ccRCC. Currently, TKIs such as sunitinib and sorafenib have been approved as the standard treating strategy for metastatic ccRCC [5]. However, there is still a subgroup of patients who have no response to such therapy and a number of patients have resistance over time. Therefore, it is of great importance to explore new molecular markers that will help us to evaluate the treating response and prognosis, furthermore, to develop novel therapies.
Cyclin-dependent kinase 5 (CDK5), a serine/threonine kinase, is a member of CDKs, but it is unique among common CDKs with no cell cycle or mitotic function because of lacking classical mediator of cell-cycle transition [6]. Previous studies have identified that CDK5 is important in neuronal development, neuronal function, and neuronal disease [7]. The investigation of CDK5 function in extra-neuronal tissues is increasing as well [8], especially in cancer research. Recently, emerging evidence showed that CDK5 played an important role in cancer tumorigenesis and progression. For example, CDK5 has been reported to highly express in hepatocellular carcinomas and promote tumor vessels formation though directly stabilizing the HIF-1α [9, 10], and CDK5 also participated in regulating the migration of prostate cancer cells [11]. Furthermore, the association between high CDK5 expression and poor prognosis has showed in other human malignancies, such as pancreatic cancer [12], lung cancer [13], thyroid carcinoma [14]. While, Sun Y et al. reported that lower expression of CDK5 associated with poorer prognosis in gastric cancer [15]. Yet, there is no research about CDK5’s function which focusing on ccRCC patients. As is known to all, pVHL tumor suppressor that participate in regulating cell proliferation [6]. Previous studies have identified that CDK5 is involved in my department for quantitative real-time PCR and Western blot analysis, and patients’ information were showed in Additional file 1: Table S1. The study was performed with the approval of the ethics committee of Zhongshan hospital. Written informed consent for each participant was obtained.

Immunohistochemistry
Tissue microarrays (TMAs) were made using above 150 tissues in Shanghai Outdo Biotech Company (Shanghai, China) including tumor tissue and adjacent tissues. The immunohistochemistry (IHC) was performed by the streptavidin-peroxidase method (Zymed Laboratories Inc., San Francisco, CA, USA). The CDK5 antibody was purchased from abcam (ab407773, Cambridge, MA, USA) and diluted into 1:50. The p21 (CDKN1A) antibody was purchased from Cell signaling technology (CST) (mAb#2947, Danvers, MA, USA) and diluted into 1:50 as well. CDK5 and p21 IHC score were determined by both the intensity and percentage of tumor cell. The intensity of staining was classified as 0 (negative), 1 (weak), 2 (moderate), 3 (strong), and the percentage was assigned as following: 1 (0–25%), 2 (26–50%), 3 (51–75%), 4 (>75%) (Additional file 1: Figure S2). The total IHC staining score was calculated by intensity × percentage. The IHC score below six was defined as low expression group, while score over six was defined as high expression group. Immunostaining was assessed and examined independently by two observers (LS. Zhu and R. Ding).

RNA extraction and quantitative RT-PCR
The total RNA was extracted from 10 paired fresh and frozen ccRCC samples (100 mg each) with Trizol (1 ml), and add chloroform (200ul) according to the standard protocol with RNase free condition. And the quantification of mRNAs was performed with the SYBR Green kit (Takara Bio, Dalian, China). As following: 2X SYBR 10ul; Fp/Rp 0.5/0.5 ul; Template 1ul (or ddH2O 1ul as negative control); ddH2O 8ul. The PCR protocol was following: Predenature 95 °C 2 min; Denature 95 °C 10 s, Annealing 57 °C 30 s and Extension 72 °C 45 s for 35 cycles (BIO-RAD CFX Connect™ Real-Time System, Hercules, USA). And the qPCR data was analyzed using the 2ΔΔCt method normalized to GAPDH. CDK5 expression was presented as the fold change. PCR primers were listed as follows: human CDK5, forward 5’-AATG ACTGGGAGGAGAGGGGAG-3’, reverse 5’- TTCA CGGCGTGATATCTCAG-3’; human GAPDH, forward 5’-ACAGTCAGCGCCATCTTCG-3’ and reverse 5’- GACAAAGCTCTCC GTTCTCAG-3’.

Methods
Patients and samples
This study enrolled 150 patients with ccRCC, who underwent nephrectomy at Zhongshan hospital, Fudan University from 2008 to 2010, including 107 male and 43 female (mean age 57.0 years). Clinical and pathological information (e.g. age at surgery, gender, tumor size, pathology, TNM stage, Fuhrman degree, and all necessary follow-up messages.) for all participants included in this study were collected and then evaluated. 10 paired fresh and frozen ccRCC samples were randomized collected in my department for quantitative real-time PCR and Western bolt analysis, and patients’ information were showed in Additional file 1: Table S1. The study was performed with the approval of the ethics committee of Zhongshan hospital. Written informed consent for each participant was obtained.

Predictive control); ddH2O 8ul. The PCR protocol was following: Predenature 95 °C 2 min; Denature 95 °C 10 s, Annealing 57 °C 30 s and Extension 72 °C 45 s for 35 cycles (BIO-RAD CFX Connect™ Real-Time System, Hercules, USA). And the qPCR data was analyzed using the 2ΔΔCt method normalized to GAPDH. CDK5 expression was presented as the fold change. PCR primers were listed as follows: human CDK5, forward 5’-AATG ACTGGGAGGAGAGGGGAG-3’, reverse 5’- TTCA CGGCGTGATATCTCAG-3’; human GAPDH, forward 5’-ACAGTCAGCGCCATCTTCG-3’ and reverse 5’- GACAAAGCTCTCC GTTCTCAG-3’.
Western blot assay

Western blot procedure was performed with the protein lysates obtained from fresh tumor samples according to our previous research [19]. Equal amounts of protein samples were resolved in 10% SDS-PAGE (Bio-Red Laboratories, Inc.). Then, protein was transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Red Laboratories, Inc.). After blocking with 3% Bovine serum Albumin (BSA) for 1 h at room temperature, the membranes were separately incubated with primary anti-CDK5 antibody (1:1000; abcam ab40773, Cambridge, MA, USA.) and anti-GAPDH antibody (1:1000; CST mAb#5174, Danvers, MA, USA.) overnight at 4 °C. Following, the membranes conjugated secondary antibody for 1 h. The signal intensity was evaluated using an enhanced chemiluminescence system (GE Healthcare Life Science, Chalfont, UK).

Database analysis and survival data

The CDK5 expression level in kidney cancer was examined from both TCGA (The Cancer Genome Atlas) (https://cancergenome.nih.gov) and GENT (Gene Expression of Normal and Tumor tissues) databases (http://medicalgenome.kribb.re.kr/GENT/). The Oncomine database (http://www.oncomine.org) is a web-based database platform that incorporates 264 independent datasets and aims to collect, standardize, analyze, and deliver transcriptomic cancer data for biomedical research. We searched the key words, Gene: CDK5/p21; Analysis type: Cancer vs Normal Analysis; Cancer type: Kidney Cancer. And we set the detailed dataset, grouped by overall survival status (days). The overall survival rate was measured according to this data of 452 patients as a validation cohort.

Statistical analysis

Statistical analysis was performed using IBM SPSS statistical version 19.0. The pathological and clinical characteristics of the two groups in all cases were assessed by the χ² test or Fisher’s exact test. Survival analysis was performed using the Kaplan-Meier method and compared with a log-rank test. The Cox proportional hazards regression model was used for determining the significant prognostic factors. All p values were 2-sides and those less than 0.05 were defined significant.

Results

Expression of CDK5 and p21 in ccRCC patients

Firstly we compared the CDK5 mRNA expression in kidney cancer from both TCGA and GENT databases...
We found that the CDK5 expression was significantly lower in primary cancer tissues compared with adjacent normal tissues in TCGA \( (p < 0.0001) \). And the GENT database also showed the similar result. This result was recapitulated in fresh ccRCC samples by using qPCR assay as well (Fig. 1c). The western blot assay also showed that the protein level of CDK5 were relatively higher in normal tissues compared with the cancer tissues (Fig. 1d). Then we examined the CDK5 and p21 protein expression in ccRCC TMAs using IHC. As shown in Fig. 2, CDK5 staining showed in the cytoplasm and nuclei, while p21 localized only in the nuclei of ccRCC. CDK5 was highly detected in adjacent normal tissues than paired cancerous tissues as well as p21, with different staining intensity in different specimens. The results showed that CDK5 and p21 expression were downregulated in ccRCC compared with normal tissue.

The CDK5 expression was found to be as low group in 83 patients (55.3%), and high in 67 patients (44.7%). The p21 expression was scored as low in 97 patients (64.7%), and high in 53 (35.3%). We also classified the patients into some types according to the combination expression of CDK5 and p21 as following: CDK5 low and p21 low group \((\text{CLPL } n = 56)\), CDK5 high and p21 high group \((\text{CHPH } n = 26)\), CDK5 low and p21 high group \((\text{CLPH } n = 27)\), and CDK5 high and p21 low group \((\text{CHPL } n = 41)\).

**Relationship between clinicopathological characteristic and CDK5/p21 expression in ccRCC patients**

The patients’ clinicopathological characteristics were analyzed (Table 1). 107 (71.3%) male and 43 female (28.7%) were included in this study. Eighty four patients (56%) were older than 55 years. Among all cases, the distributions of TNM stage I + II and III + IV, accounting for 138 (92%), and 12 (8%) respectively. As the Fuhrman grade, 108 patients (72%) were classified as grade I + II, while 42 patients were classified as grade III + IV. The CDK5 expression was significantly associated with advanced TNM stage \((p = 0.042)\), and Fuhrman grade \((p = 0.035)\). Patients with lower expression of CDK5 may more likely have worse outcome. The expression of p21 was significantly related to Fuhrman grade \((p = 0.026)\) as will. Patients in the group of lower p21 expression showed high rate of Fuhrman grade III + IV. And no significant difference was observed in other factors.

**Fig. 2** Representative immunohistochemical staining images of CDK5 and p21 in 2 patients’ ccRCC and adjacent normal tissues. a d The strong staining of CDK5 in normal tissue and lower staining in cancerous tissues. e g f h. The strong staining of p21 in normal tissue and lower staining in cancerous tissues. Bar, 100 um
Lower CDK5 and p21 expression proved to be independent prognosis factor in ccRCC

In order to evaluate prognostic value of the expression of CDK5 and p21, Kaplan-Meier survival curves and log-rank tests were performed. As presented in Fig. 3a, the 3-year and 5-year survival rates in CDK5 low group were 83.1 and 69.9%, and the rates became 89.6 and 88.1% in CDK5 high group. The validation cohort showed that the 3-year and 5-year survival rates in CDK5 low group were 91.1 and 87.5%, and 93.0 and 91.3% for those with high CDK5 expression ($p = 0.038$) (Fig. 3c). The validation cohort also showed the significant difference in OS rate in p21 low and high expression ($p = 0.029$) (Fig. 3D). We further evaluated the combined prognostic value of CDK5 and p21 expression. As presented in Fig. 4, CLPL group patients have worse OS rate ($p = 0.002$), and no significant difference was observed in other group.

Further, the univariate and multivariate analyses were used to determine the independent prognostic factors for ccRCC patients (Table 2). In univariate analysis, the p21 expression level instead of CDK5 was found to be significantly associated with the OS ($p = 0.047$). And the CLPL group showed significant association as well ($p < 0.001$). Other factors such as age ($p = 0.010$), TNM stage ($p < 0.001$), Fuhrman grade ($p = 0.001$), and tumor size ($p = 0.002$) were also correlated significantly with OS. Moreover, multivariate analysis showed that CLPL ($p < 0.001$), TNM stage ($p = 0.027$), tumor size ($p = 0.011$) were proven to be independent predictors of OS for ccRCC patients.

**Discussion**

Currently, RCC patients who have underwent the nephrectomy, usually need to take regular follow-up

---

**Table 1 Baseline characteristic**

| Characteristic          | Patients | Tumoral CDK5 expression | Tumoral p21 expression |
|-------------------------|----------|-------------------------|-----------------------|
|                         | n | % | Low | High | P-value | Low | High | P-value |
| All patients            | 150 | 100 | 83  | 67   | 0.661   | 97  | 53   | 0.289   |
| Gender                  |       |   |     |      |         |     |      |         |
| Male                    | 107  | 71.3 | 58  | 49   | 0.289   | 72  | 35   |         |
| Female                  | 43   | 28.7 | 25  | 18   | 0.624   | 25  | 18   | 0.356   |
| Age (years)             |       |   |     |      |         |     |      |         |
| ≤55                     | 66   | 44  | 38  | 28   | 0.624   | 40  | 26   |         |
| >55                     | 84   | 56  | 45  | 39   |         | 57  | 27   |         |
| TNM stage               |       |   |     |      |         |     |      |         |
| I + II                  | 138  | 92  | 73  | 65   | 0.042   | 88  | 50   | 0.172   |
| III + IV                | 12   | 8   | 10  | 2    | 0.066   | 10  | 2    | 0.435   |
| pT stage                |       |   |     |      |         |     |      |         |
| T1 + T2                 | 139  | 92.7 | 74  | 65   | 0.066   | 89  | 50   |         |
| T3 + T4                 | 11   | 7.3 | 9   | 2    |         | 8   | 3    |         |
| pN stage                |       |   |     |      |         |     |      |         |
| N0                      | 147  | 98  | 82  | 65   | 0.439   | 96  | 50   | 0.279   |
| N1                      | 3    | 2   | 1   | 2    |         | 1   | 2    |         |
| pM stage                |       |   |     |      |         |     |      |         |
| M0                      | 150  | 100 | 84  | 66   | 0.035   | 97  | 53   | 0.026   |
| M1                      | 0    | 0   | 0   | 0    |         | 0   | 0    |         |
| Fuhrman grade           |       |   |     |      |         |     |      |         |
| I + II                  | 108  | 72  | 54  | 54   | 0.250   | 64  | 44   | 0.393   |
| III + IV                | 42   | 28  | 29  | 13   |         | 33  | 9    |         |
| Tumor size (cm)         |       |   |     |      |         |     |      |         |
| ≤4                      | 75   | 50  | 45  | 30   | 0.035   | 51  | 24   |         |
| >4                      | 75   | 50  | 38  | 37   |         | 46  | 29   |         |
examinations, including blood test, computed tomography annually, in order to find recurrences as soon as possible and predict the long-term outcomes. The biomarker for evaluating and predicting the prognostic survival is still limited, so it is necessary to find new effective biomarker. In this study, we firstly demonstrated the notable association between low CDK5 expression and advanced ccRCC pathological features. Though, there was no significance observed in OS outcome, patients with low CDK5 expression seem to have poor prognosis. And the co-expression of CDK5 and p21 were also proven to be an independent prognostic factor in ccRCC patients.

The functional roles of CDK5 were well studied in the nervous system because it was discovered and characterized initially in the brain tissues [20]. CDK5 performs its significant role not only in the natural development of nervous system but also as a passive promoter during the development of pathological neurology disease [21]. Recently, a growing number of articles were focusing on the role of CDK5 in extra-neuronal oncology. Increasing researches have revealed that the abnormal expression of CDK5 participated in the tumor progression and metastasis across various solid malignancies, including breast cancer, lung cancer, prostate cancer, and liver cancer [22]. To date, the research of CDK5 in kidney cancer still limited, and our study focused on the expression of CDK5 in ccRCC patients, which is the most common pathological type.

p21 expression and protein activities are modified by multiple mechanism. It has been demonstrated that p21 acts as a well-known tumor suppressor in various types of cancers, because p21 is one of the most important target in p53 signaling pathway and functioned as cell-cycle checking point to inhibit cancer cell over proliferation [23]. In our previous work, we also found that inhibition of LSD1 would suppress the ccRCC growth through upregulating p21 signaling. Lately, Pao-Hsuan Huang and colleagues reported CDK5 could directly target p21, and overexpression of CDK5 triggered the degradation of p21 and promoted several cancer cells (breast cancer, prostate cancer, lung cancer) growth [24]. However, no studies have focused on the prognostic values of CDK5 and the combination of CDK5 and p21 in ccRCC patients. In this study, we found that both CDK5 and p21 were downregulated in cancer tissues compared with normal side, and lower CDK5 expression was significantly associated with advanced TNM stage ($p = 0.042$), and Fuhrman grade ($p = 0.035$), lower p21 was significant associated with Fuhrman grade.
grade ($p = 0.026$) either. What’s more important, the patients with combination of low CDK5 and low p21 (CLPL) showed poorer survival than other groups in Fig. 4b. CLPL patients also have worse survival compared with CHPL group ($p = 0.034$) and CLPH group ($p = 0.019$) respectively. No significant OS rate difference was observed in other groups. It’s worth mentioning that the patients in CDK5 high and p21 high group seem to have a better outcome (Fig. 4b), but the patients’ number is so limited that larger sample is needed.

Also, we suggested that the combination value of CDK5/p21 might integrate to the current model in predicting survival of ccRCC patients as an independent prognostic factor. However, large sample of patients is still needed to verify the prognostic value of CDK5/p21, and the basic mechanism within CDK5 and p21 is required in future studies.

**Conclusion**

Taken together, in our study, we tested the expression of CDK5 and the combination of CDK5 and p21 expression in ccRCC patients. The overall survival curves based on the combined CDK5 and p21 expression in ccRCC patients. (a) Different group of Patients in OS analysis. (b) CLPL group was compared with the other groups. (c) The OS analysis of patients in CLPL group and CHPL group. (d) The OS analysis of patients in CLPL group and CLPH group.

| Variables                              | Univariate analysis | Multivariate analysis |
|----------------------------------------|---------------------|----------------------|
|                                        | HR (95% CI)         | p*                   | HR (95% CI)         | p*       |
| CDK5 expression (low vs high)          | 0.486               | 0.214–1.104          | 0.085               |          |
| p21 expression (Low vs High)           | 0.375               | 0.142–0.985          | 0.047               | 0.369    | 0.162–0.839 | 0.078 |
| CDK5/p21 expression (CLPL vs Other)    | 0.310               | 0.143–0.672          | 0.003               | 0.229    | 0.102–0.515 | < 0.001|
| Age (< 55 vs > 55)                     | 1.047               | 1.011–1.084          | 0.010               | 1.022    | 0.986–1.060 | 0.237 |
| TNM stage (I + II vs III + IV)         | 6.972               | 2.935–16.563         | < 0.001             | 2.920    | 1.129–7.556 | 0.027 |
| Fuhrman grade (I + II vs III + IV)     | 5.043               | 2.359–10.781         | 0.001               | 3.299    | 0.776–6.254 | 0.138 |
| Tumor size (< 4 vs > 4)                | 4.247               | 1.721–10.479         | 0.002               | 3.490    | 1.329–9.164 | 0.011 |

**Table 2** Summary of univariate and multivariate Cox regression analysis of OS duration in all ccRCCs

CLPL CDK5 low/p21 low, HR hazard ratio, 95% CI 95% confidence interval
p21 in ccRCC samples in the first time. The data suggested that the both CDK5s and p21 were acting as promising biomarkers in ccRCC patients, and CDK5/p21 is closely associated with worse pathological outcome. This may provide the new target for therapeutic intervention in ccRCC patients.

Additional file

**Additional file 1: Figure S1.** The mRNA expression of specific gene after LSD1 inhibition in ccRCC cell lines (RNA-seq data). **Figure S2.** Representative images of IHC staining of CDKS and p21. **Figure S3.** The comparation of overall survival rate of CHPH patients with others. **Table S1.** Patients' information of the fresh samples. Age (range 42–72 years old). (DOCX 9 kb)

Abbreviations

cCRCC: clear cell Renal Cell Carcinoma; CDKS: cyclin-dependent kinase 5; CHPP: CDK5 high and p21 high group; CHPL: CDK5 high and p21 low group; CLHH: CDK5 low and p21 high group; CLPL: CDK5 low and p21 low group; GENT: Gene Expression of Normal and Tumor tissue; HIF: Hypoxia-Inducible transcription Factor; IHC: Immunohistochemistry; OS: Overall Survival; RCC: Renal cell carcinoma; TCGA: The Cancer Genome Atlas; TKIs: Tyrosine Kinase Inhibitors; TMA: Tissue Microarray; VHL: Von Hippel-Lindau

Acknowledgements

None.

Authors' contributions

LS.Z wrote the main manuscript text. L.S. Z and R. D. collected the data and prepared the figures and Tables. Z.M. L and J. Z. carried out experiments and developed the database. J.P. critically read the text and polished the English writing. All authors have read and approved the final submitted manuscript.

Funding

The collection, analysis, and materials in this work were supported by Shanghai Science and Technology Development Foundation (17JC1400904).

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This investigation was approved by the Ethics and Research Committees of Zhongshan Hospital, Fudan University, and was conducted in accordance with the ethical standards and according to the Declaration of Helsinki and according to national and international guidelines. All specimens were obtained from patients with written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Urology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China. 2Department of Obstetrics and Gynecology, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 3Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, 1630 Dong Fang Road, Shanghai, China.

Received: 28 February 2019 Accepted: 2 July 2019

Published online: 16 July 2019

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.

2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.

3. Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikers S, Kemeny LA. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615–21.

4. Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C, Russo P. Epidemiology of renal cell carcinoma. Eur Urol. 2018.

5. Takyar S, Diaz J, Sehgal M, Sapunar F, Pandha H. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials. Anti-Cancer Drugs. 2016;27(5):383–97.

6. Dhavan R, Tsai LH. A decade of CDK5. Nat Rev Mol Cell Biol. 2001;2(10):749–58.

7. Cruz JC, Tsai LH. A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease. Curr Opin Neurobiol. 2004;14(3):390–4.

8. Liebl J, Furst R, Vollmar AM, Zahler S. Twice switched at birth: cell cycle-independent roles of the “neuro-specific” cyclin-dependent kinase 5 (CDK5) in non-neuronal cells. Cell Signal. 2011;23(11):1698–707.

9. Ehrlich SM, Liebl J, Ardelt MA, Leh T, de Torni EN, May D, Brandl L, Kirchner T, Zahler S, Gerbes AL, et al. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma—a novel therapeutic approach. J Hepatol. 2015;63(1):102–13.

10. Herzog J, Ehrlich SM, Pflitzer L, Liebl J, Frohlich T, Arnold GJ, Mikultits W, Haider C, Vollmar AM, Zahler S. Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1alpha: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma. Oncotarget. 2016;7(19):27088–21.

11. Strock CJ, Park JJ, Nakakura BK, Bova GS, Isaacs JT, Ball DW, Nelkin BD. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res. 2006;66(15):7509–15.

12. Feldmann G, Mishra A, Hong SM, Bish S, Strock CJ, Ball DW, Goggins M, Maitra A, Nelkin BD. Inhibiting the cyclin-dependent kinase CDKS blocks pancreatic cancer cell formation and progression through the suppression of Ras-Ral signaling. Cancer Res. 2010;70(11):4460–9.

13. Demelash A, Rudrabhatia P, Pant HC, Wang X, Amin ND, McWhite CD, Naizhen X, Linnoila RI. Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway. Mol Biol Cell. 2012;23(15):2856–66.

14. Pozo K, Castro-Rivera E, Tan C, Plattner F, Schwach G, Siegl V, Meyer D, Guo A, Gundara J, Mettbach G, et al. The role of CDK5 in neuroendocrine thyroid cancer. Cancer Cell. 2013;24(4):499–511.

15. Sun YQ, Xie JW, Chen PC, Zheng CH, Li P, Wang JB, Lin JX, Lu J, Chen QY, Cao LL, et al. Low expression of CDKS and p27 are associated with poor prognosis in patients with gastric Cancer. J Cancer. 2016;7(9):1049–56.

16. Schoedel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P, Moley JR. Hypoxia, hypoxia-inducible transcription factors, and renal cancer. Eur Urol. 2016;69(4):464–77.

17. Hsu FN, Chen MC, Lin KC, Peng YT, Li PC, Lin E, Chiang MC, Hsieh JT, Lin H. Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser (7(2)(7)) on STAT3 in prostate cancer cells. Am J Phys Endocrinol Metab. 2013;305(8):E975–E9.

18. Abbas T, Dutta A, p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):404–13.

19. Zhu L, Wang J, Kong W, Huang J, Dong B, Huang Y, Xue W, Zhang J. LSD1 inhibition suppresses the growth of clear cell renal cell carcinoma via upregulating P21 signaling. Acta Pharm Sin B. 2019;9(2):324–34.

20. Hsianaga S, Erdö R. Regulation and role of cyclin-dependent kinase activity in neuronal survival and death. J Neurochem. 2010;115(5):1309–21.

21. Su SC, Tsai LH. Cyclin-dependent kinases in brain development and disease. Annu Rev Cell Dev Biol. 2011;27:465–91.

22. Lenjisa JL, Tadesse S, Khair NZ, Kumarasiri M, Yu M, Albrecht H, Milne R, Wang S. CDKS in oncology: recent advances and future prospects. Future Med Chem. 2017;9(16):1939–62.
23. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501–12.

24. Huang PH, Chen MC, Peng YT, Kao WH, Chang CH, Wang YC, Lai CH, Hsieh JT, Wang JH, Lee YT, et al. Cdk5 directly targets nuclear p21CIP1 and promotes Cancer cell growth. Cancer Res. 2016;76(23):6888–900.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.